These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 36272139)
21. LncRNA UCA1/miR-182-5p/MGMT axis modulates glioma cell sensitivity to temozolomide through MGMT-related DNA damage pathways. Cheng M; Wang Q; Chen L; Zhao D; Tang J; Xu J; He Z Hum Pathol; 2022 May; 123():59-73. PubMed ID: 35219686 [TBL] [Abstract][Full Text] [Related]
22. USP19 regulates DNA methylation damage repair and confers temozolomide resistance through MGMT stabilization. Liu J; Wang K; Zhu Q; Zhang Y; Chen Y; Lou Z; Yuan J CNS Neurosci Ther; 2024 Apr; 30(4):e14711. PubMed ID: 38644551 [TBL] [Abstract][Full Text] [Related]
23. Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma. Gonzalez-Aponte MF; Damato AR; Trebucq LL; Simon T; Cárdenas-García SP; Cho K; Patti GJ; Golombek DA; Chiesa JJ; Rubin JB; Herzog ED J Neurooncol; 2024 Feb; 166(3):419-430. PubMed ID: 38277015 [TBL] [Abstract][Full Text] [Related]
24. Lnc-TALC promotes O Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733 [TBL] [Abstract][Full Text] [Related]
29. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. Kitange GJ; Carlson BL; Mladek AC; Decker PA; Schroeder MA; Wu W; Grogan PT; Giannini C; Ballman KV; Buckner JC; James CD; Sarkaria JN J Neurooncol; 2009 Mar; 92(1):23-31. PubMed ID: 19011762 [TBL] [Abstract][Full Text] [Related]
30. PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency. Montaldi AP; Lima SCG; Godoy PRDV; Xavier DJ; Sakamoto-Hojo ET Oncol Rep; 2020 Nov; 44(5):2275-2287. PubMed ID: 32901889 [TBL] [Abstract][Full Text] [Related]
31. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression. Perazzoli G; Prados J; Ortiz R; Caba O; Cabeza L; Berdasco M; Gónzalez B; Melguizo C PLoS One; 2015; 10(10):e0140131. PubMed ID: 26447477 [TBL] [Abstract][Full Text] [Related]
32. Enhancing Temozolomide (TMZ) chemosensitivity using CRISPR-dCas9-mediated downregulation of O Yousefi Y; Nejati R; Eslahi A; Alizadeh F; Farrokhi S; Asoodeh A; Mojarrad M J Neurooncol; 2024 Aug; 169(1):129-135. PubMed ID: 38762829 [TBL] [Abstract][Full Text] [Related]
33. Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression. Yu Z; Chen Y; Wang S; Li P; Zhou G; Yuan Y Cancer Lett; 2018 Aug; 428():77-89. PubMed ID: 29705182 [TBL] [Abstract][Full Text] [Related]
34. Unveiling the role of TAGLN2 in glioblastoma: From proneural-mesenchymal transition to Temozolomide resistance. Li Y; Wang X; Xu T; Xu F; Chen T; Li Z; Wang Y; Chen H; Ming J; Cai J; Jiang C; Meng X Cancer Lett; 2024 Aug; 598():217107. PubMed ID: 38992489 [TBL] [Abstract][Full Text] [Related]
35. Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines. Fishman H; Monin R; Dor-On E; Kinzel A; Haber A; Giladi M; Weinberg U; Palti Y J Neurooncol; 2023 May; 163(1):83-94. PubMed ID: 37131108 [TBL] [Abstract][Full Text] [Related]
36. Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance. Zhou J; Tong F; Zhao J; Cui X; Wang Y; Wang G; Kang C; Liu X; Wang Q Cancer Biol Med; 2023 Jun; 20(5):385-400. PubMed ID: 37283490 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma. Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370 [TBL] [Abstract][Full Text] [Related]
38. mTOR inhibition and levels of the DNA repair protein MGMT in T98G glioblastoma cells. Smalley S; Chalmers AJ; Morley SJ Mol Cancer; 2014 Jun; 13():144. PubMed ID: 24909675 [TBL] [Abstract][Full Text] [Related]
39. NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition. Tsai CY; Ko HJ; Chiou SJ; Lai YL; Hou CC; Javaria T; Huang ZY; Cheng TS; Hsu TI; Chuang JY; Kwan AL; Chuang TH; Huang CF; Loh JK; Hong YR Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072831 [TBL] [Abstract][Full Text] [Related]
40. Human translesion DNA polymerases ι and κ mediate tolerance to temozolomide in MGMT-deficient glioblastoma cells. Latancia MT; Leandro GDS; Bastos AU; Moreno NC; Ariwoola AA; Martins DJ; Ashton NW; Ribeiro VC; Hoch NC; Rocha CRR; Woodgate R; Menck CFM DNA Repair (Amst); 2024 Sep; 141():103715. PubMed ID: 39029375 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]